NasdaqGM - Nasdaq Real Time Price USD

Trevi Therapeutics, Inc. (TRVI)

Compare

4.1700

+0.5700

(+15.83%)

At close: December 13 at 4:00:01 PM EST

4.1700

0.00

(0.00%)

After hours: 7:58:23 PM EST

Trevi’s chronic cough trial in IPF subjects continues without sample size change

The trial has enrolled 75% of its targeted participants.

Clinical Trials Arena yesterday

TRVI
+15.83%
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

On Thursday, Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The CORAL trial is a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27mg, 54mg, and 108mg twice daily) compared to placebo in IPF patients with

Benzinga yesterday

TRVI
+15.83%
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, which requires no change to the current sample size for the tri

PR Newswire 2 days ago

TRVI
+15.83%
Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 9 days ago

TRVI
+15.83%
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced positive results from the human abuse potential (HAP) study of oral nalbuphine.

PR Newswire 10 days ago

TRVI
+15.83%
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, at 1:00p.m. ET. Held from December 3-5 in New Yo

PR Newswire 23 days ago

TRVI
+15.83%
Q3 2024 Trevi Therapeutics Inc Earnings Call

Q3 2024 Trevi Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

TRVI
+15.83%
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...

Despite a rise in net loss, Trevi Therapeutics Inc (TRVI) advances in clinical trials and maintains a strong cash position to support future growth.

GuruFocus.com last month

TRVI
+15.83%
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter ended September 30, 2024, as well as provided business updates.

PR Newswire last month

TRVI
+15.83%
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended Sep

PR Newswire last month

TRVI
+15.83%
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.

On September 30, 2024, Rosalind Advisors, Inc. (Trades, Portfolio), a significant investment firm, executed a notable transaction involving the shares of Trevi Therapeutics Inc. (NASDAQ:TRVI). This adjustment represents a -46.10% change in their previous holding, impacting their portfolio by -1.65%. This move has adjusted the firm's position in Trevi Therapeutics to 1.03% of their holdings, reflecting a strategic shift in their investment approach towards this biopharmaceutical company.

GuruFocus.com last month

TRVI
+15.83%
$Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough$

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025.

PR Newswire last month

TRVI
+15.83%
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November.

PR Newswire last month

TRVI
+15.83%
Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Despite increased net losses and R&D expenses, Trevi Therapeutics Inc (TRVI) advances its clinical trials with a strong cash position and strategic hires.

GuruFocus.com 2 months ago

TRVI
+15.83%
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs.

PR Newswire 2 months ago

TRVI
+15.83%
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).

PR Newswire 2 months ago

TRVI
+15.83%
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9.

PR Newswire 2 months ago

TRVI
+15.83%
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at the European Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11. The presentation will take place on September 8th.

PR Newswire 3 months ago

TRVI
+15.83%
Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls

Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls

The Fly 3 months ago

DG

ANF

TRVI
+15.83%
Trevi Therapeutics to Participate in September Investor and Medical Conferences

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in September.

PR Newswire 3 months ago

TRVI
+15.83%

Performance Overview

Return	TRVI	S&P 500
YTD	+211.19%	+26.86%
1-Year	+233.60%	+30.31%
3-Year	+383.20%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Trevi Therapeutics, Inc. (TRVI)

Trevi’s chronic cough trial in IPF subjects continues without sample size change

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Q3 2024 Trevi Therapeutics Inc Earnings Call

Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Performance Overview